S&P Small Cap IJR - オプションチェーン | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
ETF
アメリカ
AMEX
iShares Core S&P Small Cap (IJR)
iShares Core S&P Small Cap (IJR) オプション

iShares Core S&P Small Cap (IJR)

107.26

-1.39

(-1.28%)

終了 3月7日 6:00AM

107.26

0.00

( 0.00% )

プレマーケット: 9:19PM

IJR ライブオプションフロー

オプションコール

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
95.00	12.10	12.90	0.00	12.50	0.00	0.00 %	0	0	-
100.00	7.40	8.20	0.00	7.80	0.00	0.00 %	0	0	-
101.00	6.50	7.20	0.00	6.85	0.00	0.00 %	0	0	-
102.00	5.70	6.50	0.00	6.10	0.00	0.00 %	0	0	-
103.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
104.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
105.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
106.00	2.95	3.60	0.00	3.275	0.00	0.00 %	0	0	-
107.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
108.00	1.65	2.40	2.56	2.025	0.00	0.00 %	0	28	-
109.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
110.00	0.85	1.60	1.07	1.225	0.00	0.00 %	0	10	-
111.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
112.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
113.00	0.15	0.60	0.35	0.375	-0.10	-22.22 %	4	19	2025/3/07
114.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
115.00	0.05	0.45	0.10	0.25	-0.70	-87.50 %	1	87	2025/3/07
116.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-

個人投資家向けのプロ仕様のツール。

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
95.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
100.00	0.30	0.75	0.45	0.525	0.00	0.00 %	0	50	-
101.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
102.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
103.00	0.80	1.50	1.25	1.15	0.00	0.00 %	0	1	-
104.00	1.10	1.65	1.05	1.375	0.00	0.00 %	1	0	2025/3/07
105.00	1.60	2.00	1.28	1.80	0.00	0.00 %	1	30	2025/3/07
106.00	1.65	2.35	1.05	2.00	0.00	0.00 %	0	2	-
107.00	2.05	3.00	0.71	2.525	0.00	0.00 %	0	2	-
108.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
109.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
110.00	2.25	4.60	4.20	3.425	0.00	0.00 %	0	50	-
111.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
112.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
113.00	6.00	6.90	6.20	6.45	3.75	153.06 %	7	32	2025/3/07
114.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
115.00	7.80	8.50	6.70	8.15	0.00	0.00 %	0	30	-
116.00	8.70	9.50	9.60	9.10	0.00	0.00 %	0	14	-

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
SUNESUNation Energy Inc	US$ 0.4683 (164.43%)	101.04M
PSTVPlus Therapeutics Inc	US$ 2.22 (54.17%)	15.75M
HFBLHome Federal Bancorp Inc of Louisiana	US$ 19.85 (53.88%)	5
BBGIBeasley Broadcast Group Inc	US$ 9.99 (53.46%)	37
VTVTvTv Therapeutics Inc	US$ 25.00 (49.88%)	4
LUNRIntuitive Machines Inc	US$ 7.14 (-36.59%)	1.46M
SYRESpyre Therapeutics Inc	US$ 13.01 (-36.54%)	69
PROVProvident Financial Holdings Inc	US$ 11.20 (-24.78%)	18
USCBUSCB Financial Holdings Inc	US$ 14.20 (-20.89%)	12
BFINBankFinancial Corporation	US$ 10.21 (-20.48%)	25
SUNESUNation Energy Inc	US$ 0.4683 (164.43%)	101.04M
FAMIFarmmi Inc	US$ 0.3179 (39.06%)	35.41M
PSTVPlus Therapeutics Inc	US$ 2.22 (54.17%)	15.75M
CTMXCytomX Therapeutics Inc	US$ 0.7751 (25.56%)	15.54M
ICONIcon Energy Corporation	US$ 0.154 (6.21%)	6.93M

StayHumble

StayHumble 3分前

💹$HYCM💹on the SILVER screen✅the GoldenGlobe✅💹

$7.00 or Nothing

$7.00 or Nothing 3分前

IB_ is a SHE?

Wow - I can't imagine it - sorry - it does not work for me...

rodman

The race to market is on and the big boy Pfizer cannot bully UEEC!
CelluSTAT Hemostatic Gauze IS the proven hemostasis product.
Gel and foam will need to pass many FDA obstacles!

https://clinicaltrials.gov/search?cond=hemostat&viewType=Table&checkSpell=
Jump on bo

tulla236a

tulla236a 4分前

are there cracks starting in the dam?

https://x.com/xMarketNews/status/1897755482753765633

SC8

Apparently human trial standards are lower in India than USA. FDA was emphatic that effective dosages be worked out before they would authorize human trials. It appears RDGL is still messing with dosages and Indian authorities gave green light to phase 2 anyway.

Again, we know FDA i

Roofus

They are compared to if Betaglue had been treating them.

$7.00 or Nothing

$7.00 or Nothing 6分前

Making it CLEAR once and for all:
when a company is bought or merges with another company, do all partnerships with financial implication need to be disolved?
Not necessarily! When a company is bought or merges with another, the fate of its financial partnerships depends on several fac

work-n-hard

work-n-hard 6分前

MLGO: In https://investorshub.advfn.com/uimage/uploads/2025/3/7/cvtwlScreenshot_2025-03-07_at_07-30-46_MLGO_SharpCharts_StockCharts.com.png

europa7

europa7 6分前

"...usdc on @hedera is live on @cryptocom..."

HBAR Foundation
@HBAR_foundation
Mar 7, 2025
https://x.com/HBAR_foundation/status/1897947502436888594

"...usdc on @hedera is live on @cryptocom..."

https://x.com/cryptocom
***

elks

What y’all say where is a good play at?

stocktowatch

stocktowatch 7分前

$CVM CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
https://finance.yahoo.com/news/cel-sci-reports-fiscal-q1-133000994.html

KISSINGER

KISSINGER 7分前

ZENADRONE Benefits from Chinese tariffs?? You need to be in business to benefit. ZENA is only in the business of fluff, hype and lies.

This POS is going to buite it hard just like EPAZD and all the other PASSLEY deals before it. Arent you embarassed Shaun?? Probably not since you hav

work-n-hard

work-n-hard 7分前

BURU: Searching for bottom https://investorshub.advfn.com/uimage/uploads/2025/3/7/deesvScreenshot_2025-03-07_at_07-29-18_BURU_SharpCharts_StockCharts.com.png

Konaploinks

Konaploinks 7分前

What if Heterogeneous quantum computing using software defined quantum computing along with trapped ion, superconducting and photonic methods along with classical to handle the data side ?

That’s a powerful and promising approach! Heterogeneous quantum computing (HQC) that integrate

stocktowatch

stocktowatch 8分前

$VSEE News : VSee Health Secures $444K County Government Contract, Expanding Market Reach in Public Sector Healthcare https://finance.yahoo.com/news/vsee-health-secures-444k-county-132600239.html

GhosTraderX

GhosTraderX 8分前

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of T

georgie18

georgie18 8分前

CODX...513...🥳... https://schrts.co/rvyEWJUJ ...https://finance.yahoo.com/news/co-diagnostics-inc-wins-dismissal-203000850.html

georgie18

Member Level
Re: georgie18 post# 670573

Friday, January 10, 2025 4:03:21 PM

Post#

Guzzi62

Guzzi62 8分前

Quote: Neither will big pharma inject any cash in this company!

And you know this how? Do you have contacts within every BP?

You are just guessing.

My guess (and hope) is that a big player is ready with $ as soon as we get approval.

Since

georgie18

georgie18 8分前

CODX...513...🥳... https://schrts.co/rvyEWJUJ ...https://finance.yahoo.com/news/co-diagnostics-inc-wins-dismissal-203000850.html

georgie18

Member Level
Re: georgie18 post# 670573

Friday, January 10, 2025 4:03:21 PM

Post#

work-n-hard

work-n-hard 9分前

AEON: In https://investorshub.advfn.com/uimage/uploads/2025/3/7/jlikqScreenshot_2025-03-07_at_07-27-27_AEON_SharpCharts_StockCharts.com.png

TurboStar97

TurboStar97 9分前

Any idea when we get our cash + shares?

Chiron

President Musk will send the Dow to 60K and usher in a new glorious era of manifest destiny for the USA. Btw, why did he let that old guy from 'the apprentice' address congress, was he sick or something?

Golden Cross

Golden Cross 10分前

$ALLR Big News Yesterday-->> Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
https://globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-An

Golden Cross

Golden Cross 12分前

$ALLR Big News Yesterday-->> Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
https://globenewswire.com/news-release/2025/03/06/3038114/0/en/Allarity-Therapeutics-An

Aavegotchi GHST Token

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約